Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Core Insights - Atossa Therapeutics has made significant progress in its global intellectual property strategy for Z-endoxifen, including the issuance of a new patent in Israel, which reinforces protection for its lead program across major jurisdictions [1][4]. Intellectual Property Developments - The Israeli patent (No. 304863) was granted on July 2, 2025, and covers oral, delayed-release dosage forms with at least 90% by weight Z-endoxifen, along with specific impurity limits and defined release characteristics [2][4]. - The patent also includes claims related to manufacturing methods that enhance the Z-isomer through stepwise crystallization and solvent control, aligning with Atossa's quality-by-design approach [2][4]. Patent Renewal and Management - Atossa received a Certificate of Patent Renewal from the Israel Patent Office, confirming the renewal status for Patent No. 304863, which supports the life-cycle management of Z-endoxifen intellectual property in Israel [3][8]. - The granted patent encompasses various aspects such as stability, delayed-release attributes, dose ranges (1–4 mg and 8 mg), and pharmacokinetic performance targets [4][8]. Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet needs in breast cancer, emphasizing disciplined capital allocation and resource focus on regulatory submissions and potential commercialization [5].